Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Equity Ratio (2016 - 2025)

Tg Therapeutics has reported Equity Ratio over the past 10 years, most recently at 0.61 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.61 for Q4 2025, up 58.34% from a year ago — trailing twelve months through Dec 2025 was 0.61 (up 58.34% YoY), and the annual figure for FY2025 was 0.61, up 58.34%.
  • Equity Ratio for Q4 2025 was 0.61 at Tg Therapeutics, up from 0.59 in the prior quarter.
  • Over the last five years, Equity Ratio for TGTX hit a ceiling of 0.81 in Q1 2021 and a floor of 0.14 in Q1 2023.
  • Median Equity Ratio over the past 5 years was 0.47 (2022), compared with a mean of 0.48.
  • Biggest five-year swings in Equity Ratio: skyrocketed 6208.9% in 2021 and later tumbled 75.28% in 2023.
  • Tg Therapeutics' Equity Ratio stood at 0.62 in 2021, then tumbled by 51.55% to 0.3 in 2022, then skyrocketed by 60.9% to 0.49 in 2023, then decreased by 20.96% to 0.38 in 2024, then soared by 58.34% to 0.61 in 2025.
  • The last three reported values for Equity Ratio were 0.61 (Q4 2025), 0.59 (Q3 2025), and 0.39 (Q2 2025) per Business Quant data.